A randomized controlled trial in both healthy Thai volunteers and Plasmodium falciparum malaria patients compared the pharmacokinetics of artesunate and mefloquine after administration of the new fixed dose artesunate-mefloquine formulation ASMQ, and the equivalent doses of the two drugs given separately. There were some differences in the pharmacokinetic profiles between the two products, but these are thought not to be biologically relevant. Exposure to both drugs was higher in patients than in healthy people.
Presentatation from: Scientific Symposium "Implementation of Artemisinin Combination Therapies (ACTs): Role of ASMQ". Rio de Janeiro, Brazil, 17 April 2008.